Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Campbell

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Oncogene|June 12, 2020
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myelomaLisa J Crawford, David C Campbell, Jonathan J Morgan, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Cardiovascular Research|April 3, 2019
NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes post-ischaemic revascularizationKarla M O'Neill, David C Campbell, Kevin S Edgar, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|October 1, 2016
Learning fiberoptic intubation on a simple model transfers to the O.RViren Naik, Edward Matsumoto, Patricia Houston, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Oncogene|June 12, 2020
The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myelomaLisa J Crawford, David C Campbell, Jonathan J Morgan, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Cardiovascular Research|April 3, 2019
NOX4 is a major regulator of cord blood-derived endothelial colony-forming cells which promotes post-ischaemic revascularizationKarla M O'Neill, David C Campbell, Kevin S Edgar, et al.
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|October 1, 2016
Learning fiberoptic intubation on a simple model transfers to the O.RViren Naik, Edward Matsumoto, Patricia Houston, et al.
Pageof 2